Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.92 |
| ▸ | PGR | P06401 | 3/20 | 0.92 |
| ▸ | TSHR | P16473 | 2/20 | 0.92 |
| ▸ | AR | P10275 | 2/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.92 |
| ▸ | MEN1 | O00255 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | APEX1 | P27695 | 1/20 | 0.92 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.92 |
| ▸ | IKBKB | O14920 | 1/20 | 0.92 |
| ▸ | CHUK | O15111 | 1/20 | 0.92 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.92 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.92 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.92 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexamethasone SCHEMBL1301204 | 1.00 | HIF1A (0.92) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL2808007 | 1.00 | HIF1A (0.92) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL2807697 | 1.00 | HIF1A (0.92) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL29199226 | 0.99 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL29199225 | 0.99 | HIF1A (0.90) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL5501682 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL73250 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL8529637 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Dexamethasone SCHEMBL1561578 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 | |
| Betamethasone SCHEMBL7426 | 0.99 | HIF1A (0.93) | HIF1ACYP3A4NR3C1HSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100506277-C | Combination of antibodies selective for tumor necrosis factor-related apoptosis-inducing ligand receptors and other therapeutic agents | UAB RESEARCH FOUNDATION (US) | 2009-07-01 | — | — | CN | claimed |
| CN-1048393-C | Aqueous drug composition having property of reversible thermosetting gelation | WAKAMOTO PHARMA CO LTD (JP) | 2000-01-19 | — | — | CN | claimed |
| CN-1097593-A | Aqueous drug composition having property of reversible thermosetting gelation | WAKAMOTO PHARMA CO LTD (JP) | 1995-01-25 | — | — | CN | claimed |
| CN-114901277-B | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-116783180-A | Tricyclic ligands for degradation of IKZF2 or IKZF4 | C4医药公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116615210-A | Novel anuclear cells as a source for the treatment of platelet-rich plasma-dependent disorders | 血小板生源说股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116390951-A | PD-L1 binding agents and uses thereof | 埃克塞里艾克西斯公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115772167-A | Compound containing urea structure and application thereof | 暨南大学 | 2023-03-10 | — | — | CN | disclosed |
| CN-115698717-A | Methods of treatment and diagnosis of cancer | 基因泰克公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-112313213-B | 3-amino pyrazole compound and application thereof | 上海海和药物研究开发股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-107207493-B | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-01-20 | — | — | CN | disclosed |
| US-5710148-A | FUMAGILLOL DERIVATIVES | SENJU PHARMACEUTICALS CO., LTD. (JP) | 1998-01-20 | — | — | US | disclosed |
| EP-0780129-A2 | Adrenal cortical steroid containing external therapeutic composition for dermatitis | CAC Corporation (JP) | 1997-06-25 | — | — | EP | disclosed |
| US-5569464-A | ENCAPSULATING DRUGS | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1996-10-29 | — | — | US | disclosed |
| EP-0730863-A2 | A corneal opacification inhibitory composition comprising a fumagillol derivative | Senju Pharmaceutical Co., Ltd. (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5506241-A | INHIBITS FIBRIN FORMATION IN ANTERIOR CHAMBER | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-04-09 | — | — | US | disclosed |
| CN-1097593-A | Aqueous drug composition having property of reversible thermosetting gelation | WAKAMOTO PHARMA CO LTD (JP) | 1995-01-25 | — | — | CN | disclosed |
| EP-0622072-A2 | Stable aqueous dispersions containing liposomes | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1994-11-02 | — | — | EP | disclosed |
| US-4983386-A | Adding amino acids to aqueous acrylic polymer solution, controlling ph; radiation resistance | TOKO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0275054-A1 | Ointment base and ointment | Toko Yakuhin Kogyo Kabushiki Kaisha (JP) | 1988-07-20 | — | — | EP | disclosed |